Bristol Myers Squibb : Immunology & Cardiovascular Presentation

Investor Series

Immunology & Cardiovascular June 26, 2020

Forward Looking Statement and Non-GAAP Financial Information

This presentation contains statements about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the Company's most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available on the SEC's website, on the Bristol-Myers Squibb website or from Bristol- Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

This presentation may include certain non-generally accepted accounting principles ("GAAP") financial measures that we use to describe our company's performance. The non-GAAP information presented provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measure are available on our website at bms.com/investors. Note that pro forma revenues in this presentation assume that the Company's acquisition of Celgene Corporation and the Otezla®divestiture occurred on January 1, 2019. Also note that a reconciliation of certain pro forma measures, however, is not provided due to no reasonably accessible or reliable comparable GAAP measures for such pro forma measures and the inherent difficulty in forecasting and quantifying such pro forma measures that are necessary for such reconciliation.

Investor Series

Giovanni Caforio

Chairman and

Chief Executive Officer

Deep portfolio for continued innovation across key therapeutic areas of focus

Immuno-OncologyHematology

Inline Brands

Immunology & CV

New Launches

1L Lung, CM-9ER

Multiple LCMs

Metastatic disease

Early stage diseaseMultiple myeloma B-cell malignancies Myeloid diseases

Inflammatory

Bowel Disease

UC - Crohn's

Other auto-immune diseases

Lupus - Psoriatic arthritis

Next Medicines

Bempeg (NKTR-214)CELMoD agents

T-cell engager (TCE)Factor XIa inhib

Next Wave

>20 assets with proof of concept decisions over the next three years

Immunology & CV Development

Samit Hirawat

Executive VP

Chief Medical Officer

Global Drug Development